Bioactive hormone predicts outcomes in critical COVID-19 patients

Medical News: COVID-19 has affected millions globally, with severe cases often leading to respiratory distress and even death. Recent research has identified a potential biomarker that could help doctors predict patient outcomes in critical cases. The study focuses on bioactive adrenomedullin (bio-ADM), a hormone involved in regulating blood vessels, which may serve as a key indicator of mortality and the need for dialysis in patients with severe COVID-19. This Medical News report highlights the study's findings and how bio-ADM could be used to help manage the treatment of critically ill patients.


Bioactive hormone predicts outcomes in critical COVID-19 patients

What the Study Explores
Bio-ADM is a vasoactive hormone that plays a critical role in maintaining the balance of fluids within the body’s blood vessels. This hormone was previously linked to various health issues, including sepsis and other critical conditions. However, in the context of COVID-19, this hormone has shown potential as a reliable predictor of mortality and complications such as acute kidney injury (AKI) and the need for dialysis in patients admitted to intensive care units (ICUs). Researchers from Lund University and Skåne University Hospital in Sweden conducted the study, which analyzed bio-ADM levels in COVID-19 patients to determine its impact on patient outcomes.
 
The Study Design
The study included 119 patients with confirmed SARS-CoV-2 infections who were admitted to two ICUs in Southern Sweden. Blood samples were taken from the patients at three intervals - upon admission to the ICU, and then on days 2 and 7. By examining the levels of bio-ADM in these samples, the researchers aimed to predict 90-day mortality rates and identify patients who would likely require dialysis. Along with blood tests, the researchers collected data on other health conditions, complications, and patient outcomes. They then used statistical models to analyze the relationship between bio-ADM levels and patient mortality and disease severity.
 
Key Findings of the Study
-Bio-ADM and Mortality Predictions
The results showed that bio-ADM levels measured on the day of ICU admission, as well as on days 2 and 7, were linked to mortality rates. The higher the bio-ADM levels, the higher the risk of death. This trend was consistent, with non-survivors showing significantly higher bio-ADM levels across all three testing periods. Interestingly, dynamic changes in bio-ADM levels between days 2 and 7 provided an even stronger prediction of mortality. In patients whose bio-ADM levels increased during this time, the risk of death was particularly high. The predictive accuracy of bio-ADM was moderate for 90-day mortality, with a concordance index ranging between 0.66 and 0.69 across the sampling days.
 
-Bio-ADM and Kidney Complications
Another crucial finding was the link between high bio-ADM levels and the need for renal replacement therapy (dialysis). Patients with elevated bio-ADM levels, especially on day 7, were more likely to require dialysis. The hormone was also associat ed with acute kidney injury (AKI), a common complication in critical COVID-19 cases. The researchers found that bio-ADM on days 2 and 7 was strongly predictive of AKI and the need for dialysis, even after adjusting for other factors like creatinine levels.
 
-Bio-ADM and Other Outcomes
Despite the strong link between bio-ADM and mortality, the hormone did not significantly predict the severity of acute respiratory distress syndrome (ARDS) in the first week of ICU stay. Additionally, bio-ADM levels were not associated with the duration of mechanical ventilation or the length of hospital stay, although there was a weak correlation between bio-ADM levels on day 7 and the total time spent in the hospital.
 
Why These Findings Matter
Bio-ADM offers a promising tool for managing critical COVID-19 cases. By measuring bio-ADM levels, healthcare providers could potentially predict which patients are at higher risk of death or serious complications, such as kidney failure, early in their treatment. This ability to forecast patient outcomes could help in making quicker and more informed decisions about who needs more aggressive treatments or closer monitoring. The fact that bio-ADM changes over time may be particularly valuable, as rising levels of the hormone suggest worsening conditions, which could signal the need for interventions before the patient’s situation deteriorates further.
 
Potential Implications for Treatment
This study suggests that bio-ADM could not only help with predicting outcomes but could also serve as a target for future treatments. One possible intervention already being explored is the use of adrecizumab, an antibody that boosts bio-ADM levels to stabilize blood vessels and prevent fluid leakage. If further studies confirm its effectiveness, adrecizumab could become part of the treatment strategy for critically ill COVID-19 patients, reducing the risk of death and organ failure.
 
Study Limitations
While the findings are promising, the researchers caution that this was a pilot study with a relatively small sample size. Larger, more diverse studies are needed to confirm the role of bio-ADM in predicting COVID-19 outcomes. Additionally, the timing of blood sample collection (which occurred after ICU admission) may have limited the study’s ability to predict the progression of the disease. Future studies should explore the benefits of testing bio-ADM levels at hospital admission, which could offer even earlier predictions of severe disease progression.
 
Conclusion
This study highlights the potential of bio-ADM as a predictor of mortality and the need for dialysis in critically ill COVID-19 patients. The findings suggest that measuring bio-ADM levels, especially changes in these levels over time, could help healthcare providers identify high-risk patients and make more informed decisions about their care. Although more research is needed to confirm these results, bio-ADM may offer a new pathway for treating severe COVID-19 cases, potentially improving survival rates and reducing complications.
 
The study findings were published in the peer-reviewed journal: Scientific Reports.
https://link.springer.com/article/10.1038/s41598-024-74380-x
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/new-study-reveals-oral-markers-may-predict-covid-19-disease-course
 
https://www.thailandmedical.news/news/study-reveals-shifts-in-key-inflammatory-markers-known-as-adipokines-in-covid-19-patients